JW Pharmaceutical's diabetes treatment 'Gardret (active ingredient Anagliptin)' [Photo by JW Pharmaceutical]
[Asia Economy Reporter Chunhee Lee] JW Pharmaceutical announced on the 11th that the results of an observational study proving the superiority of the diabetes treatment drug "Gardret (active ingredient Anagliptin)" in improving glycated hemoglobin (HbA1c) were recently published online in the international journal Diabetes Therapy. This study was conducted to demonstrate the effect of Gardret, a DPP-4 inhibitor, in patients whose blood sugar control was insufficient with other existing DPP-4 inhibitors.
Gardret is a type 2 diabetes treatment drug with Anagliptin as its main ingredient. Unlike type 1 diabetes, which occurs due to insulin deficiency, type 2 diabetes occurs when insulin is produced normally but is insufficient in quantity or ineffective due to resistance.
The research team led by Professor Sungrae Kim from the Department of Endocrinology at Bucheon St. Mary's Hospital, Catholic University, and Professor Sangyong Kim from the Department of Endocrinology and Metabolism at Chosun University Hospital conducted a study from July 2017 to March last year on 1,119 type 2 diabetes patients with HbA1c levels of 7.0% or higher who had been taking DPP-4 inhibitors other than Gardret alone or in combination for more than 8 weeks.
After switching to Gardret 100 mg, HbA1c was measured at 12 and 24 weeks. At 12 weeks, HbA1c levels improved by 0.4% compared to before administration, and at 24 weeks, by 0.42%. HbA1c levels also significantly improved in patient groups without comorbidities such as dyslipidemia, hypertension, and angina.
In the patient group without comorbidities, HbA1c levels decreased by 0.68% and 0.89% at 12 and 24 weeks, respectively. In the patient group with comorbidities, the decreases were 0.27% and 0.22%, respectively. The proportion of patients whose HbA1c levels dropped below 7% was 70% at both 12 and 24 weeks in the non-comorbid group, while it was 20% and 24% in the comorbid group, respectively.
The research team of Professors Sungrae Kim and Sangyong Kim stated, "Switching to Gardret before adding other oral hypoglycemic agents in patients without comorbidities could be a new treatment option," and added, "Not only the superior blood sugar control of Gardret but also the greater improvement effect in patients without comorbidities has been demonstrated."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
